Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated
- Black Diamond Reports Promising Phase 2 Lung Cancer Data
- Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
- Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
- Black Diamond Therapeutics files $500M mixed securities shelf